ACADIA Pharmaceuticals, Inc. (ACAD) CEO Stephen Davis on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/01/22
Acadia Pharmaceuticals (ACAD) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 03/01/22
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial ResultsBusiness Wire • 02/28/22
Will Acadia Pharmaceuticals (ACAD) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research • 02/21/22
Acadia Pharmaceuticals Announces Resubmission of Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) to Treat Alzheimer's Disease PsychosisBusiness Wire • 02/16/22
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022Business Wire • 02/14/22
Acadia Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022Business Wire • 02/11/22
Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental DiseasesBusiness Wire • 01/10/22
Will Acadia Pharmaceuticals Stock See Higher Levels After A Large 26% Rally In A Month?Forbes • 01/06/22
Acadia Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022Business Wire • 12/22/21
Acadia Slims Nuplazid Label Expansion Application For Alzheimer's Disease PsychosisBenzinga • 12/21/21
Acadia Pharmaceuticals Announces Plan for a Resubmission of its Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin)Business Wire • 12/20/21
Acadia Pharmaceuticals Announces Promotion of Mark Schneyer to Executive Vice President, Chief Financial OfficerBusiness Wire • 12/14/21